Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

Pfizer to acquire Canadian immuno-oncology company Trillium in a deal worth $2.6bn

The deal will strengthen Pfizer’s oncology offering and follows an investment of $25m in Trillium made by Pfizer in January

A holistic approach to managing pressure in MedComms

Fox&Cat

- PMLiVE

AZ to seek approval for “long-acting” COVID-19 antibodies

AZD7442 significantly reduced the risk of developing symptomatic COVID-19 in phase 3 trial and is a one-dose treatment that can be given via an intramuscular injection

regeneron headquarters

UK approves Regeneron’s COVID-19 antibody cocktail

Ronapreve is the first monoclonal antibody therapy against COVID-19 approved in Europe

- PMLiVE

NICE recommends Novartis’ Rydapt for advanced SM treatment

The twice-daily, oral drug improves overall survival of people with the rare blood disorder

Initiative Health welcomes Life Sciences by Stickyeyes

Initiative Health launched as a division of media agency Initiative in June 2021

- PMLiVE

Who cares… about great healthcare creative?

Prestigious awards for healthcare communications tend to be dominated by the big network agencies and their offshoots. And the work deserves the wins. Imaginative, innovative, powerful, arresting – it’s all...

11 London

- PMLiVE

COVID-19 vaccine protection wanes over time, backing up the need for boosters

While both Pfizer/BioNTech and AstraZeneca’s vaccines offer good protection, a new UK study shows the protection reduces over time and the UK's booster campaign is likely to begin in September

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery

Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve...

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links